BMRN β€” BIOMARIN PHARMACEUTICAL INC

Ownership history in Bayesian Capital Management, LP  Β·  9 quarters on record

This page tracks every 13F SEC filing in which Bayesian Capital Management, LP reported a position in BIOMARIN PHARMACEUTICAL INC (BMRN). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β€” sourced directly from SEC EDGAR 13F filings.

πŸ” Peak position
0.4% (2025 Q1)
πŸ“Š Avg. % of fund
0.17%
πŸ“… First filed
2017 Q2
πŸ“… Last filed
2025 Q3
⏱ Quarters held
9

Position Intelligence

Bayesian Capital Management, LP Γ— BMRN AI Analytics

πŸ“‰ Bayesian Capital Management, LP underperformed the S&P 500 by –39.8% annually on this BMRN position. Timing score: 12% (1/8 decisions correct). Average cost basis: $79.80. Maximum drawdown during holding period: –47.7%.

πŸ“ˆ Position Alpha vs SPY
-39.8%
annualised excess return

❌ Significantly underperformed the S&P 500 by 39.8% ann.
4 quarters analyzed

⏱️ Timing Score
12%

⚠️ Poor timing β€” buys often preceded drops, trims preceded rallies.
1 of 8 add/trim decisions correct

πŸ’° Entry Quality
$79.80
-32.1% vs current ($54.16)

Best entry: $54.16 (2025 Q3)  Β·  Worst: $103.49 (2022 Q4)

πŸ›‘οΈ Drawdown Resilience
–47.7%
max drawdown while held

πŸ’ͺ Held through 1 major drawdown (>20%). Strong conviction under pressure.

πŸ’ͺ Fund Conviction
56%
buy-side decisions

5 adds Β· 4 trims. Bought during 2 of 5 down-price quarters. πŸ“ˆ More buys than sells across the holding period.

πŸ“‘ Position Trajectory
β†’ Stable
last 4–5 quarters trend

βš–οΈ Portfolio weight has remained relatively stable β€” conviction maintained.
Currently 0.23% of portfolio

⚠ Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ— 4 (annualised). Not investment advice.

% of Fund (quarterly)    BMRN price (monthly, adj. close)
πŸ“‹ Quarterly Holdings History 9 quarters  β–Ύ
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q3 ADDED 20,800 +10,400 +100.0% 0.23% $1.1M $54.16
2025 Q2 REDUCED 10,400 -23,700 -69.5% 0.09% $572K $54.97
2025 Q1 ADDED 34,100 +23,000 +207.2% 0.40% $2.4M $70.69
2024 Q4 REDUCED 11,100 -9,722 -46.7% 0.09% $730K $65.73
2024 Q3 ADDED 20,822 +518 +2.6% 0.17% $1.5M $70.29
2022 Q4 ADDED 20,304 +17,885 +739.4% 0.31% $2.1M $103.49
2020 Q4 REDUCED 2,419 -401 -14.2% 0.06% $212K $87.69
2020 Q3 REDUCED 2,820 -2,380 -45.8% 0.05% $215K $76.08
2017 Q2 INITIATED 5,200 β€” β€” 0.17% $472K $90.82

🏒 Other funds also holding BMRN

As of 2025 Q4 β€” sorted by position size

Krensavage Asset Management, LLC 3Y 7Y 11.02% BOONE CAPITAL MANAGEMENT LLC 3Y 7.68% Palo Alto Investors LP 3Y 7Y 6.17% Vestal Point Capital, LP 6.06% Eagle Health Investments LP 3Y 4.79% Novo Holdings A/S 3Y 7Y 3.05% Soleus Capital Management, L.P. 3Y 2.89% SECTOR GAMMA AS 3Y 7Y 2.69% Deep Track Capital, LP 3Y 2.44% Sio Capital Management, LLC 3Y 7Y 2.18%
← Back to Bayesian Capital Management, LP Holdings